SPRAVATO: Transforming the Major Depressive Disorder Landscape
The treatment of Major Depressive Disorder (MDD) is entering a new era, with SPRAVATO commercial success marking a significant milestone. SPRAVATO (esketamine), a breakthrough therapy for depression, provides rapid symptom relief, particularly for patients with treatment-resistant depression. As part of the broader latest depression treatment options and therapies 2025, SPRAVATO exemplifies...
0 Comments 0 Shares 13 Views 0 Reviews